Epstein-Barr Virus Infections Clinical Trial
Official title:
Study on Biomarkers and Causative Factors of Complicated and/or Protracted Epstein-Barr Virus-associated Infectious Mononucleosis
This observational clinical study aims at the identification of novel biomarkers and causative factors of complicated and/or protracted Epstein-Barr virus-associated infectious mononucleosis (IM). Clinical, biochemical, and routine virological data were collected from 200 patients with IM, novel analytical tools were implemented, and immunological and virological experimental data were generated using blood samples and mouthwashes. Patients have been investigated within four weeks after the onset of symptoms as well as one month and six months thereafter.
EBV-associated diseases are a severe and global health problem, and novel tools and targets for a better pathogenetic understanding, diagnosis, treatment, and prevention are clearly needed. Here we propose to use several novel experimental approaches to investigate immunological, virological, biochemical, and clinical features in an observational study on Munich IM patients. This study aims at identifying biomarkers and causative factors of protracted and/or complicated IM to facilitate the development of novel approaches to early diagnosis, therapy, and prevention of severe, life-threatening, and chronic EBV-associated diseases, including post-viral syndromes. Two hundred patients with IM onset within the last four weeks were recruited from Munich health care institutions and were re-investigated at one and six months after the onset of symptoms. A novel diagnostic scoring system was developed to indicate the severity, complexity, and protraction of symptoms. Investigated clinical parameters, including reported symptoms and physical signs of IM, as well as candidate risk factors in the medical history of patients and family members. Peripheral blood was analysed by established and novel analytical assays to determine the immunological and virological phenotypes of IM, and viral load was determined in mouthwashes. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01256853 -
Modified Vaccinia Ankara (MVA) Vaccine Study
|
Phase 1 | |
Completed |
NCT00070785 -
Protein Studies of the Epstein-Barr Virus in Ethnically Diverse Populations
|
N/A | |
Recruiting |
NCT01248598 -
The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis
|
N/A | |
Completed |
NCT00701922 -
Surveillance Study of Viral Infections Following Lung Transplantation
|
N/A | |
Recruiting |
NCT02580539 -
A Study of the Safety and Efficacy of EBV Specific T-cell Lines
|
Phase 1/Phase 2 | |
Completed |
NCT03546101 -
Early Detection of Epstein-Barr Virus Related Disease.
|
||
Recruiting |
NCT05183490 -
R-MVST Cells for Treatment of Viral Infections
|
Phase 1 | |
Completed |
NCT00058812 -
Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts
|
Phase 1 | |
Completed |
NCT01094405 -
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
|
Phase 2 | |
Terminated |
NCT05305040 -
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
|
Phase 2/Phase 3 | |
Completed |
NCT02335437 -
Chronic Fatigue Following Acute Epstein-Barr Virus Infection in Adolescents
|
N/A | |
Recruiting |
NCT04507477 -
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
|
Phase 1/Phase 2 | |
Recruiting |
NCT03266653 -
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
|
Phase 2 | |
Completed |
NCT00963248 -
EBV Infection as a Risk Factor for PTLD in Pediatric and Adult Renal Transplant Recipients
|
N/A | |
Enrolling by invitation |
NCT06027879 -
Anti-viral T-cell Therapy by Gamma Capture
|
Phase 1/Phase 2 | |
Recruiting |
NCT05592626 -
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02715752 -
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
|
N/A | |
Completed |
NCT01070797 -
Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)
|
Phase 1 | |
Completed |
NCT00058604 -
Prevention and Treatment of Epstein-Barr Virus (EBV) Lymphoma Following a Solid Organ Transplant Using EBV Specific Cytotoxic T Lymphocytes (CTLs).
|
Phase 1 | |
Completed |
NCT00058591 -
Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)
|
Phase 1 |